Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection
This study has been completed.
Study NCT00001443   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: March 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acquired Immunodeficiency Syndrome
HIV Infections
Additional conditions recognized in this trial
Communicable Diseases
Immunologic Deficiency Syndromes
Infection
Syndrome
More general conditions related to this trial
Disease
Immune System Diseases
Lentivirus Infections
Pathologic Processes
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
indinavir (MK-0639)
Additional drug interventions recognized in this trial
Indinavir
Protease Inhibitors
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services